

**BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation)	
Against:)	
)	
)	
Abby Melissa Irwin, M.D.)	Case No. 800-2016-024914
)	
Physician's and Surgeon's)	
Certificate No. A 109129)	
)	
Respondent)	
_____)	

DECISION

The attached Stipulated Surrender of License and Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on June 20, 2019.

IT IS SO ORDERED June 13, 2019.

MEDICAL BOARD OF CALIFORNIA

By: 
Kimberly Kirchmeyer
Executive Director

1 XAVIER BECERRA
Attorney General of California
2 MATTHEW M. DAVIS
Supervising Deputy Attorney General
3 LEANNA E. SHIELDS
Deputy Attorney General
4 State Bar No. 239872
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 738-9401
7 Facsimile: (619) 645-2061

8 *Attorneys for Complainant*

9

10

**BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

11

12

13

In the Matter of the Accusation Against:

Case No. 800-2016-024914

14

ABBY MELISSA IRWIN, M.D.
115 Farley Circle, Suite 304
Lewisburg, PA 17837-9252

**STIPULATED SURRENDER OF
LICENSE AND ORDER**

15

16

Physician's and Surgeon's Certificate No.
A 109129,

17

Respondent.

18

19

20

IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-entitled proceedings that the following matters are true:

21

22

PARTIES

23

1. Kimberly Kirchmeyer (Complainant) is the Executive Director of the Medical Board of California (Board). She brought this action solely in her official capacity and is represented in this matter by Xavier Becerra, Attorney General of the State of California, by LeAnna E. Shields, Deputy Attorney General.

24

25

26

27

///

28

///

1 CULPABILITY

2 8. Respondent does not contest that, at an administrative hearing, Complainant could
3 establish a prima facie case with respect to the charges and allegations contained in Accusation
4 No. 800-2016-024914, that she has thereby subjected her Physician's and Surgeon's Certificate
5 No. A 109129 to disciplinary action, and hereby surrenders her Physician's and Surgeon's
6 Certificate No. A 109129 for the Board's formal acceptance.

7 9. Respondent agrees that if she files a petition for reinstatement or relicensure, or an
8 accusation and/or petition to revoke probation is filed against her before the Medical Board of
9 California, all of the charges and allegations contained in Accusation No. 800-2016-024914 shall
10 be deemed true, correct, and fully admitted by Respondent for purposes of any such proceeding or
11 any other licensing proceeding involving Respondent in the State of California.

12 10. Respondent understands that by signing this stipulation she enables the Board to issue
13 an order accepting the surrender of her Physician's and Surgeon's Certificate No. A 109129
14 without notice to, or opportunity to be heard by, Respondent.

15 CONTINGENCY

16 11. Business and Professions Code section 2224, subdivision (b), provides, in pertinent
17 part, that the Medical Board "shall delegate to its executive director the authority to adopt a ...
18 stipulation for surrender of a license."

19 12. Respondent understands that, by signing this stipulation, she enables the Executive
20 Director of the Board to issue an order, on behalf of the Board, accepting the surrender of her
21 Physician's and Surgeon's Certificate No. A 109129 without further notice to, or opportunity to be
22 heard by, Respondent.

23 13. This Stipulated Surrender of License and Disciplinary Order shall be subject to the
24 approval of the Executive Director on behalf of the Board. The parties agree that this Stipulated
25 Surrender of License and Disciplinary Order shall be submitted to the Executive Director for her
26 consideration in the above-entitled matter and, further, that the Executive Director shall have a
27 reasonable period of time in which to consider and act on this Stipulated Surrender of License and
28 Disciplinary Order after receiving it. By signing this stipulation, respondent fully understands

1 and agrees that she may not withdraw her agreement or seek to rescind this stipulation prior to the
2 time the Executive Director, on behalf of the Medical Board, considers and acts upon it.

3 14. The parties agree that this Stipulated Surrender of License and Disciplinary Order
4 shall be null and void and not binding upon the parties unless approved and adopted by the
5 Executive Director on behalf of the Board, except for this paragraph, which shall remain in full
6 force and effect. Respondent fully understands and agrees that in deciding whether or not to
7 approve and adopt this Stipulated Surrender of License and Disciplinary Order, the Executive
8 Director and/or the Board may receive oral and written communications from its staff and/or the
9 Attorney General's Office. Communications pursuant to this paragraph shall not disqualify the
10 Executive Director, the Board, any member thereof, and/or any other person from future
11 participation in this or any other matter affecting or involving respondent. In the event that the
12 Executive Director on behalf of the Board does not, in her discretion, approve and adopt this
13 Stipulated Surrender of License and Disciplinary Order, with the exception of this paragraph, it
14 shall not become effective, shall be of no evidentiary value whatsoever, and shall not be relied
15 upon or introduced in any disciplinary action by either party hereto. Respondent further agrees
16 that should this Stipulated Surrender of License and Disciplinary Order be rejected for any reason
17 by the Executive Director on behalf of the Board, respondent will assert no claim that the
18 Executive Director, the Board, or any member thereof, was prejudiced by its/his/her review,
19 discussion and/or consideration of this Stipulated Surrender of License and Disciplinary Order or
20 of any matter or matters related hereto.

21 **ADDITIONAL PROVISIONS**

22 15. This Stipulated Surrender of License and Disciplinary Order is intended by the parties
23 herein to be an integrated writing representing the complete, final and exclusive embodiment of
24 the agreements of the parties in the above-entitled matter.


25 16. The parties agree that copies of this Stipulated Surrender of License and Disciplinary
26 Order, including copies of the signatures of the parties, may be used in lieu of original documents
27 and signatures and, further, that such copies shall have the same force and effect as originals.

28 ///

1 **ACCEPTANCE**


2 I have carefully read the above Stipulated Surrender of License and Order and have fully
3 discussed it with my attorney, James R. Rogers, Esq., and I fully understand the stipulation and
4 the effect it will have on my Physician's and Surgeon's Certificate No. A 109129. I enter into
5 this Stipulated Surrender of License and Order voluntarily, knowingly, and intelligently, and
6 agree to be bound by the Decision and Order of the Medical Board of California.

7
8 DATED: 5/16/19


9 **ABBY MELISSA IRWIN, M.D.**
Respondent

10 I have read and fully discussed with Respondent Abby Melissa Irwin, M.D. the terms and
11 conditions and other matters contained in this Stipulated Surrender of License and Order. I
12 approve its form and content.

13 DATED: 5/16/19


14 **JAMES R. ROGERS, ESQ.**
Attorney for Respondent

15
16 **ENDORSEMENT**

17 The foregoing Stipulated Surrender of License and Order is hereby respectfully submitted
18 for consideration by the Medical Board of California of the Department of Consumer Affairs.

19 Dated: 5-31-19

Respectfully submitted,

20 **XAVIER BECERRA**
Attorney General of California
21 **MATTHEW M. DAVIS**
Supervising Deputy Attorney General



22
23 **LEANNA E. SHIELDS**
Deputy Attorney General
24 *Attorneys for Complainant*
25
26
27
28

Exhibit A

Accusation No. 800-2016-024914

1 XAVIER BECERRA
Attorney General of California
2 MATTHEW M. DAVIS
Supervising Deputy Attorney General
3 LEANNA E. SHIELDS
Deputy Attorney General
4 State Bar No. 239872
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 738-9401
7 Facsimile: (619) 645-2061

8 *Attorneys for Complainant*

FILED
STATE OF CALIFORNIA
MEDICAL BOARD OF CALIFORNIA
SACRAMENTO FEB 20 20 19
BY SARA PASO ANALYST

10 BEFORE THE
11 MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
12 STATE OF CALIFORNIA

13
14 In the Matter of the Accusation Against:

Case No. 800-2016-024914

15 **ABBY MELISSA IRWIN, M.D.**
115 Farley Circle, Suite 304
16 Lewisburg, PA 17837-9252

A C C U S A T I O N

17 **Physician's and Surgeon's Certificate**
18 **No. A 109129,**

Respondent.

19
20
21 Complainant alleges:

22 **PARTIES**

23 1. Kimberly Kirchmeyer (Complainant) brings this Accusation solely in her official
24 capacity as the Executive Director of the Medical Board of California, Department of Consumer
25 Affairs (Board).

26 2. On or about August 7, 2009, the Medical Board issued Physician's and Surgeon's
27 Certificate No. A 109129 to Abby Melissa Irwin, M.D. (Respondent). The Physician's and
28 Surgeon's Certificate expired on May 31, 2017, and has not been renewed.

JURISDICTION

1
2 3. This Accusation is brought before the Board, under the authority of the following
3 laws. All section references are to the Business and Professions Code (Code) unless otherwise
4 indicated.

5 4. Section 2227 of the Code states:

6 “(a) A licensee whose matter has been heard by an administrative law judge of
7 the Medical Quality Hearing Panel as designated in Section 11371 of the Government
8 Code, or whose default has been entered, and who is found guilty, or who has entered
9 into a stipulation for disciplinary action with the board, may, in accordance with the
10 provisions of this chapter:

11 “(1) Have his or her license revoked upon order of the board.

12 “(2) Have his or her right to practice suspended for a period not to exceed one
13 year upon order of the board.

14 “(3) Be placed on probation and be required to pay the costs of probation
15 monitoring upon order of the board.

16 “(4) Be publicly reprimanded by the board. The public reprimand may include a
17 requirement that the licensee complete relevant educational courses approved by the
18 board.

19 “(5) Have any other action taken in relation to discipline as part of an order of
20 probation, as the board or an administrative law judge may deem proper.

21 “(b) Any matter heard pursuant to subdivision (a), except for warning letters,
22 medical review or advisory conferences, professional competency examinations,
23 continuing education activities, and cost reimbursement associated therewith that are
24 agreed to with the board and successfully completed by the licensee, or other matters
25 made confidential or privileged by existing law, is deemed public, and shall be made
26 available to the public by the board pursuant to Section 803.1.”

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

5. Section 2234 of the Code, states, in pertinent part:

“The board shall take action against any licensee who is charged with unprofessional conduct. In addition to other provisions of this article, unprofessional conduct includes, but is not limited to, the following:

“(a) Violating or attempting to violate, directly or indirectly, assisting in or abetting the violation of, or conspiring to violate any provision of this chapter.

“(b) Gross negligence.

“(c) Repeated negligent acts. To be repeated, there must be two or more negligent acts or omissions. An initial negligent act or omission followed by a separate and distinct departure from the applicable standard of care shall constitute repeated negligent acts.

“(1) An initial negligent diagnosis followed by an act or omission medically appropriate for that negligent diagnosis of the patient shall constitute a single negligent act.

“(2) When the standard of care requires a change in the diagnosis, act, or omission that constitutes the negligent act described in paragraph (1), including, but not limited to, a reevaluation of the diagnosis or a change in treatment, and the licensee’s conduct departs from the applicable standard of care, each departure constitutes a separate and distinct breach of the standard of care.

“...”

6. Section 2242 of the Code states, in pertinent part:

“(a) Prescribing, dispensing, or furnishing dangerous drugs as defined in Section 4022 without an appropriate prior examination and a medical indication, constitutes unprofessional conduct.

“...”

///
///
///

1 7. Section 2266 of the Code states:

2 "The failure of a physician and surgeon to maintain adequate and accurate
3 records relating to the provision of services to their patients constitutes unprofessional
4 conduct."

5 8. Section 118 of the Code states, in pertinent part:

6 "(a) The withdrawal of an application for a license after it has been filed with a
7 board in the department shall not, unless the board has consented in writing to such
8 withdrawal, deprive the board of its authority to institute or continue a proceeding
9 against the applicant for the denial of the license upon any ground provided by law or
10 to enter an order denying the license upon any such ground.

11 "(b) The suspension, expiration, or forfeiture by operation of law of a license
12 issued by a board in the department, or its suspension, forfeiture, or cancellation by
13 order of the board or by order of a court of law, or its surrender without the written
14 consent of the board, shall not, during any period in which it may be renewed,
15 restored, reissued, or reinstated, deprive the board of its authority to institute or
16 continue a disciplinary proceeding against the licensee upon any ground provided by
17 law or to enter an order suspending or revoking the license or otherwise taking
18 disciplinary action against the licensee on any such ground.

19 "(c) As used in this section, >board= includes an individual who is authorized by
20 any provision of this code to issue, suspend, or revoke a license, and 'license'
21 includes 'certificate,' 'registration,' and 'permit.'"

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1 FIRST CAUSE FOR DISCIPLINE

2 (Gross Negligence)

3 9. Respondent has subjected her Physician's and Surgeon's Certificate No. A 109129 to
4 disciplinary action under sections 2227 and 2234, as defined by 2234, subdivision (b), of the
5 Code, in that she committed gross negligence in her care and treatment of Patients A, B and C,¹ as
6 more particularly alleged hereinafter:²

7 Patient A

8 10. On or about 2013, through on or about 2016, Respondent treated Patient A for,
9 among other things, adult attention deficit hyperactivity disorder and depression.

10 11. From on or about 2013, through on or about 2016, Respondent prescribed several
11 controlled substances to Patient A, including, but not limited to, diazepam³ and Adderall.⁴

12 12. During the period from on or about September 9, 2014, through on or about
13 November 20, 2016, according to the Controlled Substance Utilization Review and Evaluation
14 System⁵ (CURES) report for Patient A, Respondent issued seven (7) prescriptions for 60 tablets
15 of diazepam (10 mg), two per day, to Patient A.

16
17 ¹ To protect the privacy of all patients involved, patient names have not been included in this pleading.
Respondent is aware of the identity of the patients referred to herein.

18 ² Conduct occurring more than seven (7) years from the filing date of this Accusation is for informational
19 purposes only and is not alleged as a basis for disciplinary action.

20 ³ Diazepam, brand name Valium, is a Schedule IV controlled substance pursuant to Health and Safety Code
21 section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.
Diazepam is a benzodiazepine commonly used to treat anxiety. Diazepam is also indicated for treatment of
22 withdrawal and seizures.

23 ⁴ Adderall is a brand name for dextroamphetamine and amphetamine, a Schedule II controlled substance
24 pursuant to Health and Safety Code section 11055, subdivision (d), and a dangerous drug pursuant to Business and
Professions Code section 4022. It is an amphetamine salts used for attention-deficit hyperactivity disorder and
narcolepsy. Adderall carries a black box warning indicating that it has high abuse potential.

25 ⁵ The Controlled Substance Utilization Review and Evaluation System (CURES) is a program operated by the
26 California Department of Justice (DOJ) to assist health care practitioners in their efforts to ensure appropriate
prescribing of controlled substances, and law enforcement and regulatory agencies in their efforts to control diversion
27 and abuse of controlled substances. (Health & Saf. Code, § 11165.) California law requires dispensing pharmacies to
report to the DOJ the dispensing of Schedule II, III, and IV controlled substances as soon as reasonably possible after
28 the prescriptions are filled. (Health & Saf. Code, § 11165, subd. (d).) It is important to note that the history of
controlled substances dispensed to a specific patient based on the data contained in CURES is available to a health care
practitioner who is treating that patient. (Health & Saf. Code, § 11165.1, subd. (a).)

1 13. During the period from on or about September 10, 2015, through on or about May 29,
2 2016, according to the CURES report for Patient A, Respondent issued eight (8) prescriptions for
3 124 tablets of Adderall (20 mg), four per day, to Patient A.

4 14. Respondent's medical records for Patient A do not indicate any mental status or
5 physical examination was performed by Respondent prior to prescribing diazepam and Adderall
6 to Patient A.

7 15. Respondent's medical records for Patient A do not adequately indicate the quantities
8 and dosages of the prescriptions for Adderall, a Schedule II controlled substance, issued to Patient
9 A.

10 16. Respondent committed gross negligence in her care and treatment of Patient A, which
11 included, but is not limited to, failing to perform a mental status or physical examination of
12 Patient A prior to prescribing potentially addictive medication, Adderall, to Patient A.

13 **Patient B**

14 17. On or about 2013, through on or about 2016, Respondent treated Patient B for, among
15 other things, anxiety, attention deficit disorder, depression and fibromyalgia.

16 18. From on or about 2013 through on or about 2016, Respondent prescribed several
17 controlled substances to Patient B, including, but not limited to, clonazepam,⁶ alprazolam,⁷
18 Adderall,⁸ and zolpidem.⁹

19 ///

20 ///

21 _____
22 ⁶ Clonazepam, brand name Klonopin, is a Schedule IV controlled substance pursuant to Health and Safety
23 Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.
It is an anti-anxiety medication in the benzodiazepine family.

24 ⁷ Alprazolam, brand name Xanax, is a Schedule IV controlled substance pursuant to Health and Safety Code
25 section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.
Alprazolam is a short-acting benzodiazepine, high doses of alprazolam are indicated for panic disorder and severe
generalized anxiety disorder.

26 ⁸ See Footnote 4, above.

27 ⁹ Zolpidem, brand name Ambien, is a Schedule IV controlled substance pursuant to Health and Safety Code
28 section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions Code section 4022.
Zolpidem is a sedative commonly used to treat insomnia.

1 19. During the period from on or about September 27, 2013, through on or about July 17,
2 2016, according to the CURES report for Patient B, Respondent issued sixty (60) prescriptions
3 for Adderall to Patient B. The prescriptions were issued monthly and varied in quantity and
4 strength, ranging between thirty (30) and ninety (90) tablets per prescription, and 20 mg to 30 mg
5 in strength.

6 20. During the period from on or about September 27, 2013, through on or about
7 September 1, 2016, according to the CURES report for Patient B, Respondent issued fifty-four
8 (54) prescriptions for clonazepam to Patient B. The prescriptions were issued monthly and varied
9 in quantity and strength, ranging between sixty (60) and ninety (90) tablets per prescription, and 1
10 mg to 2 mg in strength.

11 21. During the period from on or about June 24, 2014, through on or about August 14,
12 2016, according to the CURES report for Patient B, Respondent issued twenty-eight (28)
13 prescriptions for Xanax to Patient B. The prescriptions were issued monthly and prescribed
14 ninety (90) tablets of Xanax (1 mg), three per day, to Patient B.

15 22. According to Respondent's medical records for Patient B, on or about September 27,
16 2013, Patient B reported to have lost his medications or believed his medications had been stolen.
17 Respondent then issued new prescriptions to Patient B for Adderall, clonazepam and Remeron.¹⁰

18 23. According to Respondent's medical records for Patient B, on or about January 15,
19 2014, Patient B reported experiencing increased anxiety. Respondent then verbally contacted
20 Patient B's pharmacy and issued a prescription for sixty (60) tablets of clonazepam, increasing
21 the dose from 1 mg to 2 mg, and issued another prescription for ninety-six (96) tablets of
22 Adderall (20 mg), to Patient B.

23 24. According to Respondent's medical records for Patient B, on or about April 7, 2014,
24 Patient B reported an unexpected death in the family. Respondent then issued a prescription for

25 ///

26 _____
27 ¹⁰ Remeron is the brand name for mirtazapine, a dangerous drug pursuant to Business and Professions Code
28 section 4022, commonly used to treat depression.

1 thirty (30) tablets of Adderall XR¹¹ (20 mg); thirty (30) tablets of Adderall (30 mg); sixty (60)
2 tablets of Clonazepam (2 mg), and Remeron, to Patient B.

3 25. According to Respondent's medical records for Patient B, on or about September 29,
4 2014, Patient B reported his roommate had stolen his medications. Respondent then issued a
5 prescription for sixty (60) tablets of Adderall (30 mg), two per day, to Patient B.

6 26. According to Respondent's medical records for Patient B, no further records were
7 prepared or maintained by Respondent after Patient B's visit on September 29, 2014.

8 27. According to CURES, Respondent continued prescribing Adderall, clonazepam, and
9 alprazolam, to Patient B through 2016.

10 28. Respondent's medical records for Patient B do not adequately record a mental status
11 examination, diagnosis, and treatment plan for Patient B. Respondent's medical records for
12 Patient B do not adequately document changes in symptoms, Patient B's response to treatment,
13 changes in treatment plan, medications, or rationale for changes in prescriptions.

14 29. Respondent's medical records for Patient B do not adequately indicate the quantities
15 and dosages of the prescriptions for Adderall, a Schedule II controlled substance, issued to Patient
16 B.

17 30. Respondent committed gross negligence in her care and treatment of Patient B, which
18 included, but is not limited to, failing to document her rationale for simultaneously prescribing
19 two separate benzodiazepines, Xanax and Clonazepam, to Patient B, or monitor for adverse side
20 effects or signs of dependence.

21 **Patient C**

22 31. Respondent did not maintain any medical records for Patient C.

23 32. During the period from on or about April 17, 2014, through on or about January 19,
24 2016, according to the CURES report for Patient C, Respondent issued eighteen (18)
25 prescriptions for Ambien¹² to Patient B. The prescriptions were issued approximately once per
26 month, each prescribing thirty (30) tablets of Ambien (10 mg), one per day, to Patient C.

27 ¹¹ Adderall XR is the extended release version of Adderall. See Footnote 4, above.

28 ¹² Ambien is the brand name for zolpidem. See Footnote 9, above.

1 33. During the period from on or about April 15, 2014, through on or about April 27,
2 2015, according to the CURES report for Patient C, Respondent issued eleven (11) prescriptions
3 for ninety (90) tablets of alprazolam (2 mg), three per day, to Patient C.

4 34. On or about July 9, 2015, August 25, 2015, and October 29, 2015, according to the
5 CURES report for Patient C, Respondent issued three (3) prescriptions for sixty (60) tablets of
6 alprazolam (2 mg), two per day, to Patient C.

7 35. On or about January 19, 2015, March 12, 2015, and April 17, 2015, according to the
8 CURES report for Patient C, Respondent issued three (3) prescriptions for sixty (60) tablets of
9 Adderall (20 mg), two per day, to Patient C.

10 36. On or about July 26, 2014, according to the CURES report for Patient C, Respondent
11 issued a prescription for ninety (90) tablets of Valium¹³ (10 mg), to Patient C.

12 37. On or about October 27, 2014, November 26, 2014, and January 19, 2015, according
13 to the CURES report for Patient C, Respondent issued three (3) prescriptions for twelve (12) to
14 fourteen (14) capsules of Librium¹⁴ (25 mg), to Patient C.

15 38. On or about January 19, 2015, according to the CURES report for Patient C,
16 Respondent issued a prescription for ninety (90) tablets of oxycodone,¹⁵ to Patient C.

17 39. On or about January 21, 2015, according to pharmacy records for Patient C,
18 Respondent issued a prescription for ninety (90) tablets of Flexeril,¹⁶ to Patient C.

19 ///

20 _____
21 ¹³ Valium is the brand name for diazepam. See Footnote 3, above.

22 ¹⁴ Librium is the brand name for chlordiazepoxide. Librium is a Schedule IV controlled substance pursuant
23 to Health and Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and Professions
Code section 4022. Librium is a benzodiazepine, commonly used to treat anxiety and withdrawal.

24 ¹⁵ Oxycodone is a Schedule II controlled substance pursuant to Health and Safety Code section 11055,
25 subdivision (b), and a dangerous drug pursuant to Business and Professions Code section 4022. When properly
26 prescribed and indicated, it is used for the treatment of moderate to moderately severe pain. The Drug Enforcement
Administration (DEA) has identified opioids, such as oxycodone, as a drug of abuse. (Drugs of Abuse, DEA
Resource Guide (2015 Edition), at p. 43.)

27 ¹⁶ Flexeril is the brand name for cyclobenzaprine, a dangerous drug pursuant to Business and Professions
28 Code section 4022. Flexeril is a muscle relaxant, commonly used to treat muscle pain.

1 40. On or about February 15, 2015 and March 14, 2015, according to pharmacy records
2 for Patient C, Respondent issued prescriptions for sixty (60) tablets of Clonidine,¹⁷ to Patient C.

3 41. On or about November 8, 2016, December 7, 2016, January 3, 2017 and March 6,
4 2017, according to pharmacy records for Patient C, Respondent issued prescriptions for 120
5 tablets of Neurontin¹⁸ (300 mg), to Patient C.

6 42. Respondent committed gross negligence in her care and treatment of Patient C, which
7 included, but were not limited to, the following:

- 8 (a) Respondent failed to perform a mental status and/or physical examination of
9 Patient C prior to prescribing potentially addictive medications to Patient C;
10 (b) Respondent failed to document her rationale for prescribing large quantities of
11 Xanax to Patient C, or her rationale for prescribing Valium and Librium, while
12 also prescribing Xanax, to Patient C;
13 (c) Respondent failed to maintain adequate and accurate medical records pertaining
14 to her care and treatment provided to Patient C; and
15 (d) Respondent failed to maintain adequate and accurate medical records pertaining
16 to her prescribing Schedule II controlled substances to Patient C.

17 **SECOND CAUSE FOR DISCIPLINE**

18 **(Repeated Negligent Acts)**

19 43. Respondent has further subjected her Physician's and Surgeon's Certificate No.
20 A 109129 to disciplinary action under sections 2227 and 2234, as defined by 2234, subdivision
21 (c), of the Code, in that she committed repeated negligent acts in her care and treatment of
22 Patients A, B and C, as more particularly alleged hereinafter:

- 23 (a) Paragraphs 10 through 42, above, are hereby incorporated by reference and
24 realleged as if fully set forth herein;

25 _____
26 ¹⁷ Clonidine is a dangerous drug pursuant to Business and Professions Code section 4022. Clonidine is
27 commonly used to treat high blood pressure, attention deficit hyperactivity disorder, anxiety and withdrawal.

28 ¹⁸ Neurontin, brand name for gabapentin, is a dangerous drug pursuant to Business and Professions Code
section 4022. Neurontin is commonly used to treat nerve pain and seizures.

- 1 (b) Respondent failed to maintain adequate and accurate medical records pertaining
2 to her prescribing Schedule II controlled substances, Adderall, to Patient A;
3 (c) Respondent failed to maintain adequate and accurate medical records pertaining
4 to her prescribing Schedule II controlled substances, Adderall, to Patient B; and
5 (d) Respondent failed to maintain adequate and accurate medical records pertaining
6 to her care and treatment provided to Patient B.

7 **THIRD CAUSE FOR DISCIPLINE**

8 **(Prescribing Without an Appropriate Prior Examination or Medical Indication)**

9 44. Respondent has further subjected her Physician's and Surgeon's Certificate No.
10 A 109129 to disciplinary action under sections 2227, and 2234, as defined by 2242, of the Code,
11 in that she prescribed, dispensed, or furnished dangerous drugs as defined in section 4022 without
12 an appropriate medical indication, in her care and treatment of Patients A and C, as more
13 particularly alleged in paragraphs 10 through 16, and 31 through 42, above, which are hereby
14 incorporated by reference and realleged as if fully set forth herein.

15 **FOURTH CAUSE FOR DISCIPLINE**

16 **(Failure to Maintain Adequate and Accurate Records)**

17 45. Respondent has further subjected her Physician's and Surgeon's Certificate No.
18 A 109129 to disciplinary action under sections 2227 and 2234, as defined by 2266, of the Code,
19 in that she failed to keep adequate and accurate medical records in her care and treatment of
20 Patients A, B and C, as more particularly alleged in paragraphs 10 through 43, above, which are
21 hereby incorporated by reference and realleged as if fully set forth herein.

22 **FIFTH CAUSE FOR DISCIPLINE**

23 **(Violations of the Medical Practice Act)**

24 46. Respondent has further subjected her Physician's and Surgeon's Certificate No.
25 A 109129 to disciplinary action under sections 2227 and 2234, as defined by 2234, subdivision
26 (a), of the Code, in that she committed a violation or violations of a provision or provisions of the
27 Medical Practice Act in her care and treatment of patients A, B and C, as more particularly

28 ///


1 alleged in paragraphs 10 through 45, above, which are hereby incorporated by reference and
2 realleged as if fully set forth herein.

3 PRAYER

4 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
5 and that following the hearing, the Medical Board of California issue a decision:

- 6 1. Revoking or suspending Physician's and Surgeon's Certificate No. A 109129, issued
7 to Respondent Abby Melissa Irwin, M.D.;
- 8 2. Revoking, suspending or denying approval of Respondent Abby Melissa Irwin,
9 M.D.'s authority to supervise physician assistants and advanced practice nurses;
- 10 3. Ordering Respondent Abby Melissa Irwin, M.D., if placed on probation, to pay the
11 Board the costs of probation monitoring; and
- 12 4. Taking such other and further action as deemed necessary and proper.

13
14 DATED:
15 February 20, 2019


16 KIMBERLY KIRCHMEYER
17 Executive Director
18 Medical Board of California
19 Department of Consumer Affairs
20 State of California
21 Complainant

22
23
24
25
26
27
28
SD2019700055
71716189